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Introduction
Recent data suggest that Toll-like receptors (TLRs)
participate in the development of  cancer through
direct influence on the growth of tumor cells, as well
as through the modulation of antitumor activity and
survival of the immune cells [1]. Neutrophils (PMNs),
the primary effector cells of the early phase of the
immune response to tumor, express the majority of the
11 human TLRs, which initiate different biological
functions of these cells [2]. It has been reported that
PMNs' stimulation through TLR2 causes an immediate
defensive response, including e.g. cytokine production
and secretion [2,3]. Detailed research has revealed that
TLR2 is coexpressed with TLR6 on the neutrophils
and has the ability to form heteromers with TLR6 to
mediate the intracellular signaling, leading to survival
or apoptotic cell death [4-7]. 
Two distinct apoptotic signaling pathways in
human neutrophils have been identified: the intrinsic
pathway, regulated by members of the Bcl-2 family
proteins and the extrinsic pathway, associated with
TNF superfamily proteins involving FasL, TNF or
TNF-related apoptosis-inducing ligand (TRAIL). Neu-
trophils constitutively express pro-apoptotic Bax and
anti-apoptotic Mcl-1 proteins, belonging to Bcl- 2
family [8]. It has been well established that Bax, by
fusion with mitochondria upon apoptosis, results in the
permeabilization of the outer membrane, with subse-
quent release of proapoptotic proteins, such as
cytochrome c, Smac/DIABLO and HtrA2/Omi [8].
Cytochrome c binds to apoptotic protease-activating
factor-1 (Apaf-1), which recruits procaspase-9. In this
complex procaspase-9 undergoes an autoproteolytic
transformation to caspase-9. Smac/Diablo and HtrA2/
Omi are antagonists of inhibitors of apoptosis pro-
teins (IAPs) that are required to relieve the inhibited
caspases [9]. 
The expression of proapototic or antiapoptotic
members of the Bcl-2 family in neutrophils is con-
trolled by the activation of transcriptional signaling
pathways that involve the mitogen - activated protein
kinase p38 (p38MAPK) [10]. The same kinase is acti-
vated by the stimulation of TLRs receptors [7]. Addi-
tionally, TLRs can play a significant role in the regula-
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tion of Bcl-2 family proteins. It was reported that TLR2
and TLR6 activation can delay apoptosis through the
modulation of anti-apoptotic Bcl-2 family proteins,
associated with increased levels of Mcl-1 and A1 [7]. 
Our previous study showed the acceleration of
apoptosis in PMNs derived from oral cavity cancer
patients and suggested that this process may be
dependent on the decreased expression of anti-apop-
totic Mcl-1 protein, which accompanied the
unchanged pro-apoptotic Bax expression [11]. In order
to better understand the mechanisms responsible for
shortened survival of neutrophils in this patient group
we took interest in the involvement of TLR2 and
TLR6, as well as p38 MAPK, in Mcl-1-mediated
apoptosis in those cells. Additionally, to confirm the
lack of engagement of pro-apoptotic proteins of Bcl-2
family in this process, we examined the expression of
Smac/DIABLO proteins, cytochrome c release and cas-
pase-9 activity, which are initiated not only by Bax but
also by other proapoptotic proteins of Bcl-2 family. 
Materials and methods
Sample material. The examination involved 20 patients (average
age 49 years)  with  squamous cell carcinoma of oral cavity, under-
going treatment in the Department of Oral and Maxillofacial
Surgery at Medical University of Bialystok. Examinations were
carried out on patients before the treatment and 3 weeks after the
surgical removal of the tumor mass. Patients did not receive any
treatment or medication before the examination. No clinical signs
of infection were observed in patients.  The mean number of white
cells in the blood of all patients before treatment was 6.18×103/µL
(from 3.8 to 8.95×103/µL), after treatment was 5.6×103/µL (from
4.0 to 8.25×103/µL). The study included a healthy persons as con-
trol group (n=15) (mean 41.5 years). The study was approved by
the Ethics Committee of the Medical University of Bialystok and
all patients submitted their consent in writing.
Preparation of leukocytes. For the purpose of the examinations of
the expression of TLR2, TLR6, Mcl-1, Bax, Smac/DIABLO and
p38 MAPK in PMNs and in autologous PBMCs (for comparative
purposes), the cells were isolated from anticoagulant venous blood.
PMNs and PBMCs suspensions (5 × 106 cells/mL) with purity
>94% were incubated for 20 h at 37°C. 
Western blot analysis. The protein fractions of cells were ana-
lyzed for the presence of examined proteins by Western blot, as
previously described [12]. 
Apoptosis evaluation. Annexin V binding of neutrophils was per-
formed using an apoptosis detection kit (APOTESTTM - FITC,
Nexins Research, Holland). Initially, 105 cells/ml of freshly isolat-
ed cells or incubated cells were labeled with FITC-conjugated
Annexin V and propidium iodide (PI) for 20 min at +4°C. The sam-
ples were analyzed by two-color flow cytometry using CellQest
Analysis software (Becton Dickinson, Epics Coulter, USA).
Results were reported in the form of the percentage of Annexin V-
positive cells, which reflects the relative proportion of apoptotic
cells. The percentage of cells positive for PI and Annexin V-FITC
and PI were considered as necrotic. 
Caspase-9 activity. Caspase-9 activity was measured using Cas-
pase-8 Colorimetric Assay (R&D Systems). Cell lysates were test-
ed for protease activity by means of addition of a caspase-specific
peptide, conjugated to the color reporter molecule p-nitroaniline
(pNA). The cleavage of the peptide by the caspase releases the
chromophore pNA, quantitated spectrophotometrically at a wave-
length of 405 nm. The level of caspase enzymatic activity in the
cell lysate is directly proportional to the color reaction.
Cytochrome c concentration. Cytochrome c concentrations in
cell lysates were assessed using ELISA kit (R&D systems, Min-
neapolis, USA).    
Results and discussion
The results of the present study appear to confirm the
role of TLR2 and TLR6 receptors in the apoptosis
process in PMNs from oral cavity cancer patients.
Decreased expressions of both TLR2 and TLR6, ana-
lyzed by Western blot and quantified using LabImage
1 D gel software (Fig. 1), were accompanying the
increased intensity of apoptosis in the PMNs from
patients before treatment, in comparison to the control
(12.6% and 0.65% respectively). TLRs expression in
PMNs and autologous PBMCs was on the same level.
However, the number of PBMCs with apoptotic fea-
tures in patients before and after the treatment was
similar to that of the control group (0.91% and 1.2%
respectively). The simultaneous decreased expression
of both TLRs and the decreased expression of Mcl-1
protein observed earlier appear to confirm the sugges-
tion that apoptosis of PMNs from cancer patients con-
trolled by Mcl-1 is dependent on the TLR2 and TLR6
signalling [11]. In contrast to PMNs, the absence of
changes in Mcl-1 expression in autologous PBMCs
might be associated with the unchanged intensity of
apoptosis in those cells in patients before and after
treatment (1.6%). 
Impaired TLRs expression can lead to an insuffi-
cient activation of p38 MAPK, involved in the regula-
tion of cellular Mcl-1 expression [1,10,13]. In the
examined PMNs we found a lowered expression of
phospho-p38MAPK, which is a sign of p38MAPK
activation (Fig. 2). The observation above suggests
that the low expression of TLRs and p38MAPK activ-
ity leads to the low expression of antiapoptotic Mcl-1
protein, which is responsible for the shortened lifespan
of the examined PMNs. The absence of Mcl-1 activity
in PMNs of cancer patients may be associated with the
unchanged concentration of apoptogenic cytochromee
c observed in those cells (7.07 ng/ml±4.3ng/ml and
8.84 ng/ml±3.7 ng/ml, respectively). It is known that
Mcl-1 interacts with tBid and impairs its ability to
induce cytochrome c release from mitochondria. Since
cytochrome c participates in the formation of caspase-9,
its unchanged concentration in PMNs from cancer
patients, may be associated with the absence of
changes in caspase-9 activity, demonstrated in these
cells (0.182±0.089 and 0.200±0.073, respectively).
The activity of this enzyme in autologous PBMCs
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lysates of patients (0.152±0.076, 0.147±0.09) was si-
milar to the control group level (0.142±0.064). 
The decreased expression of TLR2 and TLR6 in
PMNs, despite its effect on the apoptosis in these cells,
may have other implications for the immune defense
of cancer patients. The impaired expression of both
TLRs can lead to disturbances in the secretion of dif-
ferent anti-tumor molecules by neutrophils, such as
TNF-α or TRAIL [7,14]. TRAIL induces apoptosis in
a number of tumor cells through a complex system of
two death receptors TRAIL-R1(DR4) and TRAIL-
R2(DR5) that are expressed on head and neck squa-
mous carcinoma cells (HNSCC), making them sensi-
tive to TRAIL-mediated apoptosis [15]. The decreased
secretion of TRAIL by PMNs and PBMCs from
advanced oral cavity cancer, demonstrated in earlier
617TLR2 and TLR6 in Mcl-1-mediated apoptosis in netrophils
©Polish Histochemical et Cytochemical Society
Folia Histochem Cytobiol. 2009:47(4): 617 (615-619) 
10.2478/v10042-008-0118-8
Fig. 1. Western blot analysis of TLR2 and
TLR6 proteins expression in PMN and
PBMC of control and  oral cavity cancer
patients:  A - PMN of  control, B - PBMC
of control, C - PMN of patients before
treatment, D - PBMC of patients before
treatment, E - PMN of patients after treat-
ment, F - PBMC of patients after treatment.
The diagram below is shown statistical
analysis of Western blot for five independ-
ent samples of blood. Bands intensity was
quantified using LabImage 1 D gel soft-
ware and presented in arbitrary units. *Sta-
tistical differences between PMN and
PBMC (p<0.05). aStatistical differences
between patients and control (p<0.05).
bStatistical differences between patients
before and after treatment (p<0.05) 
study, may be responsible for impaired apoptosis of
the tumor cells [12]. It remains unclear if the changes
in the release of this proapoptotic molecule are direct-
ly associated with TLR2 and TLR6 expression in the
examined leukocytes.
In patients after the surgical treatment the increased
expression of TLR2 and TLR6, associated with the
increased expression of Mcl-1 protein and simultane-
ous delay of apoptosis in PMNs, suggests a transient
deficit of these proteins in patients before treatment,
caused by a direct or indirect activity of the tumor
cells. It was shown that tumor cells, including HNSCC
cells, can release immunosupression cytokines, such
as VEGF, which inhibit immune cells activation and
impair tumor-specific immunity [16].
The comparison of the results obtained in patients
before and after treatment appears to confirm the lack
of engagement of proapoptotic proteins belonging to
Bcl-2 family in the apoptotic process in PMNs. Despite
the lack of alterations in cytochrome c concentrations
and caspase-9 activity, the expression of
Smac/DIABLO in PMNs and PBMCs lysates of
patients and the control were on the same level (Fig. 2). 
To conclude based on the relations between the
estimated TLRs receptors, p38MAPK and Mcl-1 pro-
tein expression in confrontation with the intensity of
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Fig. 2. Western blot analysis of phospho-
p38 and Smac/Diablo proteins expres-
sion in PMN and PBMC of control and
oral cavity cancer patients:  A – PMN of
control, B – PBMC of control, C – PMN
of patients before treatment, D – PBMC
of patients before treatment, E – PMN of
patients after treatment, F – PBMC of
patients after treatment. The diagram
below is shown statistical analysis of
Western blot of Bax and Smac/DIABLO
from five independent samples of blood.
Bands intensity was quantified using
LabImage 1 D gel software and present-
ed in arbitrary units. *Statistical differ-
ences between PMN and PBMC
(p<0.05). aStatistical differences
between patients and control (p<0.05).
bStatistical differences between patients
before and after treatment (p<0.05) 
apoptosis in PMNs of patients, we can confirm the
influence of these molecules on the shortened lifespan
of neutrophils in oral cavity cancer patients. Further-
more, PMNs from oral cavity cancer patients appears
to be more sensitive in tumor microenvironment than
autologous PBMCs. Further research is necessary to
explain the dependence between the observed changes
and the clinical status of patients that may have a
potential prognostic significance and also to contribute
to the development a new immunotherapy strategy for
oral cavity cancer based on the modulation of TLRs.
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